Table 4.

Summary of respiratory-swallow phase patterns for both 5-mL trials.

	No. of patients (%)
	E–E	E–I	I–E	I–I
Age-matched controls	29 (72.5%)	2 (5.0%)	8 (20%)	1 (2.5%)
Patients with cancer	15 (37.5%)	4 (10.0%)	20 (50%)	1 (2.5%)
SURG-XRT	8 (36.4%)	3 (13.6%)	11 (50%)	0 (0.0%)
CHEMO-XRT	7 (38.9%)	1 (5.6%)	9 (50%)	1 (5.6%)

Abbreviations: E–E, swallows immediately preceded by and followed by expiratory flow; E–I, swallows immediately preceded by expiratory flow and followed by inspiratory flow; I–E, swallows immediately preceded by inspiratory flow and followed by expiratory flow; II, swallows immediately preceded by and followed by inspiratory flow; SURG–XRT, patients previously treated with surgery and radiation therapy; CHEMO–XRT, patients previously treated with chemotherapy and radiation therapy.